Tributyrin (glyceryl tributyrate) is a triglyceride ester of butyric acid that is being investigated in a Phase 1/2 clinical trial (NCT07154511) for its potential to improve cognitive function in patients with Parkinson's Disease who have cognitive impairments. The trial is sponsored by Prabesh Kanel and aims to evaluate whether tributyrin supplementation can improve memory, thinking, and motor function in PD patients [1].
Tributyrin represents an epigenetic approach to neurodegeneration, leveraging the epigenetic-modulating properties of butyric acid to potentially restore neuronal function and protect against cognitive decline. This represents a novel therapeutic strategy that addresses the underlying epigenetic dysregulation observed in Parkinson's Disease [2].
Butyric acid (butanoic acid) is a short-chain fatty acid (SCFA) produced naturally by gut microbiota through fermentation of dietary fiber. It serves as a primary energy source for colonocytes and exerts widespread effects on systemic metabolism and immune function [3].
Key Properties of Butyric Acid:
| Property | Mechanism | Therapeutic Implication |
|---|---|---|
| HDAC Inhibition | Class I/IIa histone deacetylase inhibition | Epigenetic regulation of neuroprotective genes |
| Energy Metabolism | Mitochondrial energy substrate | Enhanced neuronal energy production |
| Anti-inflammatory | NF-κB inhibition, Treg promotion | Reduced neuroinflammation |
| Gut-Brain Axis | SCFA signaling to brain | Systemic neuroprotective effects |
| Gene Expression | Histone acetylation | Upregulation of BDNF, antioxidant genes |
Tributyrin is a triglyceride form of butyric acid that offers several advantages over direct butyric acid administration:
Pharmacokinetic Advantages:
Parkinson's Disease is associated with widespread epigenetic alterations:
Histone Modifications in PD:
Tributyrin as Epigenetic Therapy:
By inhibiting HDACs, tributyrin promotes:
Trial Overview:
Primary Objectives:
Study Population:
Outcome Measures:
| Domain | Assessment Tools |
|---|---|
| Cognitive Function | Standardized neuropsychological tests |
| Motor Function | Walking/balance assessments |
| Safety | Adverse event monitoring |
| Biomarkers | Optional biomarker assessments |
Cognitive impairment is a common non-motor symptom in Parkinson's Disease, affecting up to 50% of patients over the disease course. The underlying mechanisms include:
Tributyrin's HDAC inhibitory activity may address several of these mechanisms, potentially improving cognitive function through multiple pathways.
Alzheimer's Disease Models:
Parkinson's Disease Models:
Mechanism Studies:
While direct evidence in PD is limited, studies in other neurological conditions support the therapeutic potential:
| Aspect | Description |
|---|---|
| Novel Mechanism | Epigenetic modulation distinct from dopaminergic therapies |
| Non-dopaminergic | Addresses non-motor symptoms (cognition) |
| Disease-modifying | Potential to modify underlying pathology |
| Good Safety Profile | Naturally occurring SCFA with favorable safety |
| Oral Administration | Convenient delivery route |
| Cost-effective | Lower development costs vs. novel molecules |
| Therapy | Mechanism | Status | Limitations |
|---|---|---|---|
| Tributyrin | HDAC inhibition | Phase 1/2 | Early stage |
| Cholinesterase Inhibitors | Acetylcholinesterase inhibition | Approved | Modest efficacy |
| Rivastigmine | AChE/BuChE inhibition | Approved | GI side effects |
| DA Agonists | Dopamine receptor activation | Approved | May worsen cognition |
| Deep Brain Stimulation | Neurostimulation | Approved | Invasive |
Tributyrin may be suitable for combination with:
Butyric acid and tributyrin have demonstrated favorable safety profiles:
Common (Mild):
Less Common:
Rare:
Tributyrin may interact with:
Tributyrin's mechanism intersects with the gut-brain axis, an emerging area of PD research:
Gut-Brain Axis in Parkinson's Disease:
Tributyrin Effects on Gut-Brain Axis:
Potential biomarkers for tributyrin response:
This page is maintained as part of the NeuroWiki clinical trials coverage. Last updated: 2026-03-31